INS and cancer: Patients on anti-cancer treatment who develop high blood glucose levels should be regularly monitored for levels of insulin and C-peptide, pancreatic amylase/lipase, anti-islet cell autoantibodies, anti-glutamic acid decarboxylase autoantibodies, anti-insulin antibodies and urine/capillary ketones (6).